Johnson & Johnson subsidiary Janssen gained FDA approval on 23 April for Sylvant (siltuximab), the first drug in the US to treat patients with multicentric Castleman's disease (MCD), a rare blood disorder in which lymphocytes are over-produced, leading to enlarged lymph nodes, and which also can affect the lymphoid tissue of internal organs, causing the liver, spleen or other organs to enlarge.
MCD, a proliferative disease that acts similar to lymphoma, usually affects adults who often experience fever, night sweats, weight loss...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
